Researchers at Stanford have developed a nucleic acid amplification test to detect high-risk Epstein-Barr Virus (EBV) BALF2 variants in plasma to aid population-level screening for nasopharyngeal carcinoma (NPC).
Stanford virologists have developed a quantitative and sensitive assay to detect chikungunya virus (CHIKV). In addition, it may be multiplexed with assays for other pathogens to detect and differentiate CHIKV infection.